Latest news with #AngioDynamics
Yahoo
2 days ago
- Business
- Yahoo
What Makes AngioDynamics (ANGO) a Strong Momentum Stock: Buy Now?
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. Below, we take a look at AngioDynamics (ANGO), which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions. It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. AngioDynamics currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period. You can see the current list of Zacks #1 Rank Stocks here >>> Let's discuss some of the components of the Momentum Style Score for ANGO that show why this medical device maker shows promise as a solid momentum pick. A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area. For ANGO, shares are up 7.94% over the past week while the Zacks Medical - Instruments industry is up 0.37% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 26.88% compares favorably with the industry's 1.13% performance as well. While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Shares of AngioDynamics have increased 20.07% over the past quarter, and have gained 71.09% in the last year. In comparison, the S&P 500 has only moved 2.37% and 14.4%, respectively. Investors should also take note of ANGO's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now, ANGO is averaging 535,625 shares for the last 20 days. The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with ANGO. Over the past two months, 2 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost ANGO's consensus estimate, increasing from -$0.36 to -$0.29 in the past 60 days. Looking at the next fiscal year, 2 estimates have moved upwards while there have been no downward revisions in the same time period. Taking into account all of these elements, it should come as no surprise that ANGO is a #1 (Strong Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep AngioDynamics on your short list. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
14-05-2025
- Business
- Yahoo
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Idexx Laboratories (IDXX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Idexx Laboratories is one of 1001 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Idexx Laboratories is currently sporting a Zacks Rank of #2 (Buy). The Zacks Consensus Estimate for IDXX's full-year earnings has moved 1.9% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend. Our latest available data shows that IDXX has returned about 23.2% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -6.7% on a year-to-date basis. This means that Idexx Laboratories is outperforming the sector as a whole this year. Another stock in the Medical sector, AngioDynamics (ANGO), has outperformed the sector so far this year. The stock's year-to-date return is 2.6%. In AngioDynamics' case, the consensus EPS estimate for the current year increased 22.5% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy). Breaking things down more, Idexx Laboratories is a member of the Medical - Instruments industry, which includes 85 individual companies and currently sits at #78 in the Zacks Industry Rank. Stocks in this group have lost about 6.9% so far this year, so IDXX is performing better this group in terms of year-to-date returns. AngioDynamics is also part of the same industry. Investors with an interest in Medical stocks should continue to track Idexx Laboratories and AngioDynamics. These stocks will be looking to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-04-2025
- Business
- Yahoo
Shareholders in AngioDynamics (NASDAQ:ANGO) are in the red if they invested three years ago
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been particularly tough on longer term AngioDynamics, Inc. (NASDAQ:ANGO) shareholders. So they might be feeling emotional about the 61% share price collapse, in that time. It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Given that AngioDynamics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. In the last three years AngioDynamics saw its revenue shrink by 3.5% per year. That is not a good result. The share price decline of 17% compound, over three years, is understandable given the company doesn't have profits to boast of, and revenue is moving in the wrong direction. Of course, it's the future that will determine whether today's price is a good one. We don't generally like to own companies that lose money and can't grow revenues. But any company is worth looking at when it makes a maiden profit. You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image). We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. This free report showing analyst forecasts should help you form a view on AngioDynamics We're pleased to report that AngioDynamics shareholders have received a total shareholder return of 30% over one year. Notably the five-year annualised TSR loss of 2% per year compares very unfavourably with the recent share price performance. This makes us a little wary, but the business might have turned around its fortunes. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 1 warning sign for AngioDynamics you should be aware of. AngioDynamics is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Globe and Mail
02-04-2025
- Business
- Globe and Mail
Centesis Catheters Market Worth $633 Million by 2025 – Exclusive Report by MarketsandMarkets™
"The key players operating in the global centesis catheters market are AngioDynamics, Inc. (US), ARGON MEDICAL (US), Avanos Medical Devices (US), Axiom Medical, Inc. (US), B. Braun Melsungen AG (Germany), Becton, Dickinson and Company (US), Blue Neem Medical Devices Pvt. Ltd. (India), Boston Scientific Corporation (US)" Browse 118 market data Tables and 30 Figures spread through 153 Pages and in-depth TOC on "Centesis Catheters Market by Type (Small and Large bore), Procedure (Paracentesis, Thoracentesis, Amniocentesis), Application (Diagnosis, Therapeutics and Palliative care), End user (Hospitals, Ambulatory surgery centers), Region - Global Forecast to 2025 According to the new market research report "Centesis Catheters Market by Type (Small and Large bore), Procedure (Paracentesis, Thoracentesis, Amniocentesis), Application (Diagnosis, Therapeutics and Palliative care), End user (Hospitals, Ambulatory surgery centers), Region - Global Forecast to 2025", published by MarketsandMarkets™, the Centesis Catheters Market is projected to reach USD 633 million by 2025 from USD 426 million in 2019, at a CAGR of 6.8%. Download PDF Brochure: Growth in the global centesis catheters market can be attributed to factors such as the rising target patient population (particularly patients suffering from cancer, TB, and cardiovascular diseases), growing preference for image-guided centesis procedures, and the increasing evidence for the efficacy of centesis procedures for target diseases. Small-bore centesis catheters segment accounted for the largest share of the centesis catheters market, by type, in 2018 Based on type, the centesis catheters market is segmented into small-bore and large-bore centesis catheters. The small-bore centesis catheters segment accounted for the largest share of this market in 2018. This can be attributed to the wide availability of small-bore centesis catheters, growing number of target procedures that require small-bore centesis catheters, increasing evidence of the efficacy and safety of small-bore centesis catheters over large-bore centesis catheters, and their higher adoption in diagnostic centesis procedures. Browse in-depth TOC on" Centesis Catheters Market" 118 – Tables 30 – Figures 155 – Pages Paracentesis procedures segment accounted for the largest share of the centesis catheters market, by procedure, in 2018 Based on procedure, the centesis catheters market is segmented into paracentesis, thoracentesis, arthrocentesis, amniocentesis, and other procedures. The paracentesis segment accounted for the largest share of this market in 2018. The rising incidence of target conditions such as gastrointestinal malignancies, liver cirrhosis, cystic fibrosis, intestinal tuberculosis, chronic liver failure, formation of cysts in the peritoneal cavity, and serious forms of hepatitis is expected to drive the growth of this market segment in the coming years. Hospitals were the largest end users of centesis catheters in 2018 Based on end user, the global centesis catheters market has been segmented into hospitals, ambulatory surgical centers, and other end users. The hospitals segment accounted for the largest share of the market in 2018. This is because the majority of centesis procedures are performed in hospitals owing to the risks involved in these procedures and the higher patient preference for hospital-based care for target disease conditions, such as gastrointestinal malignancies, liver cirrhosis, cystic fibrosis, intestinal tuberculosis, chronic liver failure, peritonitis, and pleural effusion. Get 10% Customization on this Research Report: Asia Pacific is the fastest-growing regional market for centesis catheters The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. This can be attributed to the presence of a large patient pool, increasing incidence and prevalence of target diseases, improving healthcare infrastructure in Asian countries, and the favorable government initiatives for improving access to healthcare. The key players operating in the global centesis catheters market are AngioDynamics, Inc. (US), ARGON MEDICAL (US), Avanos Medical Devices (US), Axiom Medical, Inc. (US), B. Braun Melsungen AG (Germany), Becton, Dickinson and Company (US), Blue Neem Medical Devices Pvt. Ltd. (India), Boston Scientific Corporation (US), Canadian Hospital Specialties Ltd. (Canada), Cardinal Health (US), Cook Medical (US), Galt Medical Corp. (US), Guangzhou Leadgem Medical Device Co., Ltd. (China), KM Medical (US), Medical Components, Inc. (US), Medtronic (Ireland), Merit Medical Systems (US), Mermaid Medical A/S (Denmark), MoFlo Medical Technology Co., Ltd. (China), Neuromedex GmbH (Germany), Ningbo Honde Medical Instruments Co., Ltd. (China), PFM Medical, Inc. (US), Polymedicure (India), REDAX (Italy), Rocket Medical plc. (UK), Romsons (India), Smiths Medical (US), Teleflex Incorporated (US), UreSil, LLC (US), and Utah Medical Products, Inc. (US).
South China Morning Post
11-02-2025
- Health
- South China Morning Post
US firm brings prostate cancer therapy to Hong Kong, cutting surgery risks
An American medical technology firm has introduced a novel treatment in Hong Kong that uses electric pulses to kill prostate cancer cells while minimising the risks of incontinence and sexual dysfunction. AngioDynamics, of Latham, New York, said its NanoKnife system delivers 'high-voltage, low-energy' electrical pulses to create irreversible electroporation (IRE), a form of damage that kills targeted cells. It was approved for marketing by the US Food and Drug Administration (FDA) in December. 'This allows a physician to destroy the targeted cells but preserve the underlying structure of the tissue,' said Jake Brumbaugh, the vice-president of oncology global marketing at the Nasdaq-listed firm. 'This unique mechanism of action means the NanoKnife system is extremely versatile, able to be used in any segment of an organ, even providing ablations across critical structures including nerves, the urethra and blood vessels.' The voltage, typically in the range of 1,500 to 3,000 volts per centimetre between electrodes, varies depending on the tissue type and treatment plan, he said. The technology offers an alternative for patients whose cancer has yet to spread outside the prostate. Prostate cancer is the fourth most common cancer worldwide and the second most common among men, with 1.47 million new cases in 2022, according to the UK-based charity World Cancer Research Fund International. Nations that reported the most cases were the US, which accounted for 15.7 per cent of the total, followed by China at 9.1 per cent.
